Advanced Cell Technology, a leader in the field of regenerative medicine, announced that chairman and CEO Gary Rabin will be delivering a presentation at the World Stem Cells and Regenerative Medicine Conference, May 21-23, in London, a conference held to promote discussion and collaboration in the stem cell and regenerative medicine industry.
Mr. Rabin’s presentation will be given today at 5:05 p.m. BST (London time). It is titled “Successes and ongoing advancements of human clinical trials for the treatment of AMD & Stargardt’s Disease.” Mr. Rabin’s presentation will detail progress on ACT’s three ongoing human clinical trials in the U.S. and E.U. for Dry Age-Related Macular Degeneration and Stargardt’s Macular Dystrophy (SMD).
In addition, ACT recently announced it has received Data and Safety Monitoring Board approval to advance the enrollment and treatment of additional patients with SMD in its U.S. SMD trial, as well as to treat the remaining two patients to finish up the initial dosing arm in its European trial. Every one of the company’s ongoing clinical trials use human embryonic stem cell derived retinal pigment epithelial cells.
For more information, please visit www.advancedcell.com
Let us hear your thoughts below:
